Programmable ASO Therapeutics

RNA Actuators create a sequence-specific approach to precisely target regRNA transcripts.

The ability to modify genes and gene expression using various therapeutic techniques has unlocked the potential to treat numerous diseases that were once considered out of reach. Yet many approaches to gene upregulation have significant limitations. By amplifying mRNA to increase gene expression and restore healthy protein levels, we believe that we can do better.

 

The Summit Approach

RAP Platform™

Our RAP Platform™ allows us to map regRNAs and select the optimal sequence to target using validated ASO chemistry.
1

Map regRNA

We use next-generation sequencing technologies powered by proprietary machine learning algorithms to map regRNAs and cell-specific genes they control.
2

Identify RNA Hotspots

We rapidly generate ASO drug candidates that target regRNA hotspots for tunable gene upregulation.
3

Program for Druggability

We design high-potency RNA Actuators for safe and effective delivery to target tissues underlying disease.

The Right Tools: RNA Actuators

 

Antisense oligonucleotides are an accurate, efficient and proven way to engage desired RNA targets. Building upon the power of this technology, our RNA Actuators can be programmed to engage regRNA targets, producing tunable increases in protein expression. We design RNA Actuators to leverage current and future delivery systems to enable drug delivery to multiple different types of tissue throughout the body.

RNA Actuators are a new category of synthetic gene regulators

Therapeutic Potential

Using RNA Actuators, we can develop therapies that overcome the limitations of other gene modulating approaches.

Adjustable Dosing

Ability to potentially re-dose or adjust dose to precisely control effects

Cell- and Tissue-Specific

Reduced risk of off-target effects that can lead to toxicity

Over a Thousand Diseases

Applicable to a broader range of diseases than other methods

We are building a deep pipeline of therapeutic candidates that have the potential to transform the treatment of a wide variety of diseases.

Learn More

Partnering to Capitalize on our Potential

Our platform enables expansive opportunities across multiple therapeutic areas. Given the enormity of the potential, we can’t do it all alone. We intend for our approach and unparalleled understanding of regRNAs, oligonucleotide technology and gene expression to open up vast horizons for drug discovery and development.

Partnering with biopharma companies with expertise in a given therapeutic area is integral to maximizing the potential of our platform for patients. Our aim is to empower partners with a rapid, efficient approach to targeting the diseases that matter most to them.

 

Learn More

Top